CFO transition in Senzime

Press release: Uppsala, May 14, 2019. Senzime AB (publ) today announces that Senzimes CFO Jessica Roxhed has resigned for personal reasons and will leave the company in August 2019.

Senzime exhibitor at SAMTIT

News: Uppsala, May 10, 2019. Senzime AB (publ) reports from SAMTIT Congress 8-10 May 2019

Communique from the annual general meeting in Senzime AB (publ)

The annual general meeting in Senzime AB (publ) was held on 8 May 2019 at the company’s offices on Ulls väg 29B in Uppsala whereby the shareholders primarily resolved on the following matters.

Senzime’s Interim report January – March 2019

Press release: Uppsala, May 8, 2019. Senzime AB’s (publ) Interim report for January – March 2018  is now available on the company’s webbsite www.senzime.com.

Senzime signs Nordic distribution agreement with Vingmed Holding A/S

Press release: Uppsala, May 6, 2019. Senzime AB (publ) today announces that it has signed an exclusive distribution agreement with Vingmed Holding A/S for the commercialization of TetraGraph in Sweden, Denmark, Norway and Finland.

Senzime Annual Summary 2018

News: Uppsala, April 25, 2019. Senzime AB’s (publ) annual summary for 2018 in English is now available on the company’s webbsite www.senzime.com.

Senzime’s Annual Report 2018

Uppsala, April 11, 2019. Senzime AB’s (publ) annual report for fiscal year 2018 (only in Swedish) is now available on the company’s webbsite www.senzime.com.

Notice of Annual General Meeting in Senzime ab (PUBL)

Press release: Uppsala, April 9, 2019. The shareholders in Senzime AB (publ) reg. no. 556565-5734 (the “Company”) are hereby convened to an annual general meeting on Wednesday 8 May 2019 at 15.00 at the Company’s office at Ulls väg 29B in Uppsala.

Senzime strengthens the management team within Sales and Marketing

Press release: Uppsala, March 28, 2019. Senzime AB (publ) today announced that the management team is strengthened with a VP Sales and a VP Marketing and Business development. This is in line with Senzime’s clear focus on international commercialization.

Senzime files new FDA application for TetraGraph

Press release: Uppsala, March 28, 2019. Senzime AB (publ) today announces the filing of the new 510(k) application to the US Food and Drug Administration (FDA) for the TetraGraph system. This filing is in line with previous communication and strategy to decrease the overall time to reach FDA clearance and subsequent introduction on the US market.

Market launch of the TetraGraph Viewer

Press release: Uppsala, March 26, 2019. Senzime AB (publ) today announces the launch of the TetraGraph Viewer, a new software, enabling data extraction and analytics from the TetraGraph patient monitor to a connected computer.

Norrlands Universitetssjukhus starts study with OnZurf Probe

Press release: Uppsala, March 25, 2019, Senzime (PUBL) today announces that Norrlands Universitetssjukhus has initiated a new exploratory pilot study with OnZurf probe. The study will include a total of 30 patients undergoing liver surgery.

Akademiska Sjukhuset in Uppsala new strategic customer to Senzime

Press release: Uppsala, March 20, 2019. Senzime AB (publ) today announces that the Department of Neuroanesthesia at the University Hospital in Uppsala has signed an agreement to buy TetraGraph systems. The agreement is of a minor value and initially includes five TetraGraph systems and associated disposable sensors.

Press conference regarding Senzime’s successful collaboration with the University of Debrecen

News: Uppsala, March 6, 2019. Senzime AB (publ) today announces that a press conference has been held at the University of Debrecen, Department of Anesthesiology and Intensive Care, focusing on their participation in testing and validating the TetraGraph during the last 5 years.

Senzime updates and optimizes strategy for FDA approval

Press release: Uppsala, February 15, 2019. Senzime AB (publ) today announces the intent to re-submit the existing 510(k) application to the US Food and Drug Administration (FDA). Based on an updated version of the TetraGraph, the existing 510(k) application will be re-submitted and Senzime thereby seeks to decrease the overall time to FDA approval.

Senzime’s Year-end Bulletin 2018

Press release: Uppsala, February 15, 2018. Senzime AB’s (publ) year-end bulletin is now available on the company’s webbsite www.senzime.com.

Pia Renaudin joins as new CEO at Senzime

Press release: Uppsala, February 7th, 2019. Pia Renaudin assumes her position as the new CEO of Senzime AB (publ).

Senzime receives milestone payment from Fukuda Denshi of approximately 2.4 million SEK

PRESS RELEASE: Uppsala, December 21, 2018. Senzime AB (publ) today announces the booking of a milestone payment of approximately 2.4 million SEK related to the license agreement and collaboration with Fukuda Denshi signed in 2016.

Senzime AB (publ) executes a directed share issue to two institutions – approximately SEK 28 million added before issue costs

Press Release: Uppsala, 12 December 2018.The Board of Directors of Senzime AB (publ) ("Senzime" or the “Company"), with the support of the authorization received at the AGM on May 8, 2018, has executed a directed share issue to Handelsbanken Fonder through the Svenska Microcapfond and Länsförsäkringar Fondförvaltning. The directed share issue comprises 4,000,000 shares at a subscription price of SEK 6.90 per share, equivalent to a premium of approximately two percent compared to the volume weighted average share price of the ten last trading days. Through the issue, the Company is granted approximately SEK 28 million before issue costs.

Pia Renaudin new CEO of Senzime

Press release: Uppsala, November 19, 2018: The Board of Senzime AB (publ) has today appointed Pia Renaudin as new Chief Executive Officer. Pia will start her new position in the first quarter of 2019, and will succeed the current CEO, Lena Söderström, who leaves Senzime after nearly six years. Catrin Molund, Director Marketing & Business Development at Senzime, will assume the role of acting CEO until Pia joins her position

Senzime’s Interim report January – September 2018

Press release: Uppsala, November 8, 2018. Senzime AB’s (publ) interim report for the period January - September is now available on the company’s webbsite www.senzime.com.

Senzime reports from the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco, USA

News: Uppsala, 17 October 2018.

Senzime signs additional distribution agreements in Europe

Press release: Uppsala, September 27, 2018. Senzime AB (publ) today announced that it signed exclusive distribution agreements for the commercialization of TetraGraph in Italy, Slovenia, Ukraine, Moldavia and Georgia.

Senzime at the Innovation Pavilion

News: Uppsala, September 4, 2018. Senzime AB (publ) has been selected to exhibit at the Innovation Pavilion at The MedTech Conference in Philadelphia, Pennsylvania September 24-26. Fourteen innovative companies have been given this opportunity by AdvaMed.   

Lena Söderström appointed Biotech Builder 2018

News: Uppsala, August 29, 2018. Lena Söderström has been appointed Biotech Builder 2018 of the year. The award is appointed to Life Science entrepreneurs who have made significant progress in the course of time, while being an inspiration for others in the industry.

Senzime’s Interim report quarter 2, 2018

Press release: Uppsala, August 22, 2018. Senzime AB’s (publ) interim report for the period January - June is now available on the company’s webbsite www.senzime.com.

TetraGraph Exhibition and Poster presentation at The Euroanaesthesia 2018 Annual Meeting, Copenhagen, Denmark, June 2-4

News: Uppsala, June 8, 2018. 

Resolutions at Senzime AB’s (publ) annual general meeting

Senzime AB (publ) (the “Company”) held its annual general meeting on May 8, 2018 in the Company’s premises on Ulls väg 29B in Uppsala.

Senzime’s Interim report January – March 2018

Uppsala, May 8, 2018. Senzime AB’s (publ) Interim report for January – March 2018 is now available on the company’s webbsite www.senzime.com.

TetraGraph Exhibition and Poster at The International Anesthesia Research Society’s (IARS) 2018 Annual Meeting, Chicago

News: Uppsala, May 4, 2018. 

Senzime ads 6 countries to the TetraGraph distribution network

Press Release: Uppsala, April 25, 2018. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in Belgium, Netherlands, Luxemburg, Austria, Czech Republic and Slovakia.

Senzime’s Annual Report 2017

Press Release: Uppsala, April 17, 2018. Senzime AB’s (publ) annual report for fiscal year 2017 (only in Swedish) is now available on the company’s webbsite www.senzime.com.

Senzime signs distribution agreement in South Korea

Press release: Uppsala, March 19, 2018. Senzime AB (publ) today announced that it signed an exclusive distribution agreement with Unimedics (unimedics.co.kr) for the commercialization of the TetraGraph in South Korea. Compensation will be paid per unit in line with current industry compensation including a minimum guaranteed sale. The registration process is estimated to be finalized during 2019.

Senzime signs additional distribution agreements for the TetraGraph

Press Release: Uppsala, March 7, 2018. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in Spain and Portugal.

Resolutions at Senzime AB’s (publ) extraordinary general meeting

Press release: Senzime AB (publ) held an extraordinary general meeting on March 5, 2018 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

Reallocation of certain shareholdings in Senzime AB (publ)

Press Release: Uppsala, February 19, 2018. During the period of 19-23 February 2018, a group of major shareholders, including two who are Board Directors of Senzime AB (publ) ("Senzime", "the Company"), will reallocate certain shareholdings. The shares will be reallocated within the group, without any consideration, as a result of a revised and agreed allocation methodology related to a previously closed acquisition.

Senzime’s Year-end Bulletin 2017

Press release: Uppsala, February 16, 2018. Senzime AB’s (publ) year-end bulletin 2017 is now available on the company’s webbsite www.senzime.com.

Notice of extraordinary general meeting in Senzime AB (publ)

The shareholders in Senzime AB (publ), reg. no. 556565-5734 (the “Company”) are hereby convened to the extraordinary general meeting at 9 AM (local time) on Monday 5 March 2018 in the office of Advokatfirman Lindahl at Vaksalagatan 10, 753 20, Uppsala.

Senzime proposes directed new issue that includes Segulah Venture AB, amounting to a total of SEK 25 million

Press Release: Uppsala, February 16, 2018. Prior to the commercialization of its products, Senzime AB (publ) (”Senzime” or ”the Company”) is proposing a directed new issue to a few strategically important investors, including Segulah Venture AB, with a maximum of 4,166,667 shares at a subscription price of SEK 6 per share, equivalent to a discount of approximately 8 per cent compared to the share weighted average price of the previous 10 trading days. Through the rights issue, the Company will receive SEK 25 million before issue costs.

Senzime signs cooperation agreement with Philips

Press release; Uppsala, January 23, 2018.  Senzime AB (publ) has signed a license and cooperation agreement with Philips to allow the TetraGraph Neuromuscular Monitoring System to communicate with Philips IntelliVue patient monitors worldwide. 

TetraGraph Poster and Abstract presentation at The Society for Technology in Anesthesia (STA) 2018

News; Uppsala, January 19, 2018. The STA 2018 Annual Meeting in Turnberry Isle Miami Aventura, Florida, January 10-13, is designated for a national and international audience of physicians, engineers and industry members, as well as other practitioners in the field of anesthesia seeking an update on the current and future state of anesthesia technology. https://www.stahq.org/events/annual-meeting

Meet Senzime at Arab Health in Dubai, 29th January – 1st February

News; Uppsala, January 8, 2018.

Meet Senzime at WSM in London, 10-12 January

NEWS; Uppsala, January 5, 2018. For over 30 years the Winter Scientific Meeting (WSM) in London has been a great way for anaesthetists to develop their specialty knowledge and network with the wider anaesthesia community over three days. http://www.wsmlondon.org/

Press release; Senzime receives CE mark approval for the OnZurf Probe

Uppsala, December 18, 2017. Senzime AB (publ) announces that the company has received CE mark approval for the OnZurf Probe, which means that the product now is approved for sale on the European market.

Press release; Senzime receives CE mark approval for the TetraGraph

Uppsala, December 12, 2017.  Senzime AB (publ) announced today that it has received CE mark approval to enable the commercialization of the TetraGraph Neuromuscular Monitoring System. 

NEWS; Consensus Statement on Perioperative Use of Neuromuscular Monitoring

Uppsala, December 11, 2017.  A panel of clinician scientists with expertise in neuromuscular blockade (NMB) monitoring was convened with a charge to prepare a consensus statement on indications for, and proper use of, such monitors. This statement was published online at www.anesthesia-analgesia.org on November 30, 2017 (2018 in press), Copyright 2017 International Anesthesia Research Society.

Senzime’s Interim report January – September 2017

Uppsala, November 28, 2017. Senzime AB’s (publ) Interim report for January – September 2017 is now available on the company’s webbsite www.senzime.com.

Meet Senzime at Medica Trade Fair in Düsseldorf, 13-16 November

Uppsala, November 8, 2017. Medica Trade Fair in Düsseldorf is the world's leading trade fair for the medical industry. The fair consists of 17 halls where exhibitors from all over the world will present their products. Welcome to meet Senzime at Medica to learn more about our patient monitoring products OnZurf Probe, CliniSenz Analyzer and TetraGraph.

Senzime reports from the American Society of Anesthesiologists (ASA)

NEWS Uppsala, 26 October 2017. Senzime reports from the American Society of Anesthesiologists (ASA) Annual Meeting in Boston, USA.